Elsevier Partners with DiabetesIndia
Singapore, November 17, 2005 – Elsevier, the world-leading scientific and medical publisher, has announced a new publishing partnership with Diabetes India (DI) and the launch of a new journal, Diabetes Research & Metabolic Syndrome in June 2006. Diabetes Research & Metabolic Syndrome will cover two main clinical areas—diabetes and metabolic syndrome focusing on both vascular damage causes and the glucose centered disease approach.
Editor of Diabetes Research & Metabolic Syndrome, Professor Philip Home noted, “Metabolic Syndrome is of particular interest from a global perspective and this gives Diabetes Research & Metabolic Syndrome its raison d’etre in an era of proliferating specialist journals in the field of diabetes. The journal is timely and should rapidly become a force in the world of cardiovascular prevention.”
“Despite the growing importance of diabetes and the metabolic syndrome worldwide, only a few medical journals are actually dedicated to these diseases,” explained Co-Editor, Professor Anoop Misra further, “We will focus on issues relating to these diseases in South Asia, China, Africa and the Middle East where 60 to 70% of the world population and diabetes patients reside—and which are sparsely represented in the mainstream diabetes journals. I am thrilled to be working with the editorial board whose members represent global leadership in diabetes and metabolic disorders, from both developed and developing countries.”
# # #
DIABETESINDIA originally named as The Indian Task Force on Diabetes Care In India was initially formed by a group of around 400 practicing diabetologists and has now opened its doors to other medical specialists, family physicians, people with diabetes and all others interested in the cause of diabetes. Today, we are proud to say that we have a membership of many thousands and this is increasing at a rapid pace. DIABETESINDIA recently carried out a first of its kind nationwide survey of the prevalence of diabetes and our published data shows that India has already exceeded the WHO projections. For more information please visit http://www.diabetesindia.com
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s nearly 7,000 employees in 77 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as Science Direct , MD Consult , Scopus, bibliographic databases, and online reference works.
Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier’s ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
- Contact Information
- Rosalia Da Garcia
- Director of Marketing & Society Relations
- Elsevier Health Sciences Asia Pacific
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.